Literature DB >> 21074352

[Chemotherapy in gallbladder carcinoma].

Halima Abahssain1, Pauline Afchain, Nawfal Melas, Nabil Ismaili, Rabia Rahali, Hind M Rabti, Hassan Errihani.   

Abstract

Gallbladder cancer is an aggressive tumor. Its incidence varies according to geography. Surgery is the standard treatment for localized stage but there is no standard treatment in metastatic or locally advanced disease. Because of the rarity of bile tract cancer (BTC) and gallblader carcinoma (GBC), most studies have grouped all BTC and GBC together, and there are very few GBC-specific studies. In addition, there is a paucity of randomized controlled studies in this disease with small numbers of patients and inclusion bias. One randomized trial ABC-02 was well conducted and showed a survival benefit in favor of gemcitabine (GEM)+cisplatin (CDDP), which can be regarded as the standard in locally advanced BTC. Adjuvant therapy after surgical resection is not validated. Understanding the molecular mechanisms of carcinogenesis of GBC has opened the way for the use of targeted therapies. This new treatment would improve survival and quality of life of our patients.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21074352     DOI: 10.1016/j.lpm.2010.09.002

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  4 in total

1.  Oxymatrine induces apoptosis and inhibits invasion in Gallbladder carcinoma via PTEN/PI3K/AKT pathway.

Authors:  Liqiang Qian; Xiaqin Li; Penghui Ye; Gang Wang; Wei Dai; Yan Liu; Quangen Gao; Genhai Shen
Journal:  Cytotechnology       Date:  2017-11-23       Impact factor: 2.058

2.  Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma.

Authors:  Xin-xing Li; Ying Dong; Wei Wang; Hao-lu Wang; Yu-ying Chen; Gui-ying Shi; Jing Yi; Jian Wang
Journal:  Stem Cells Dev       Date:  2012-11-07       Impact factor: 3.272

3.  Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition.

Authors:  Huajie Zong; Baobing Yin; Huading Zhou; Duan Cai; Baojin Ma; Yang Xiang
Journal:  Mol Biol Rep       Date:  2014-03-13       Impact factor: 2.316

4.  Long non-coding RNA CRNDE promotes gallbladder carcinoma carcinogenesis and as a scaffold of DMBT1 and C-IAP1 complexes to activating PI3K-AKT pathway.

Authors:  Sheng Shen; Han Liu; Yueqi Wang; Jiwen Wang; Xiaolin Ni; Zhilong Ai; Hongtao Pan; Houbao Liu; Yebo Shao
Journal:  Oncotarget       Date:  2016-11-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.